Japan said on Tuesday (Sept 16) it has committed 17.2 billion yen (S$222.2 million) in funds for its participation in the World Health Organisation's Covid-19 vaccine programme. But after being pulled by the drug regulator, DGCI (Drugs Controller General of India), it paused the tests.
South Korea's SK Bioscience in July agreed to manufacture AstraZeneca's experimental vaccine, which has shown promise, to help the British company build global supplies. AstraZeneca said on Saturday that an outside panel had cleared its trial in Britain to begin again, but the firm has not given any details about the patient's condition, nor has it released a transcript of the executive's remarks to investors, which were reported by the news outlet STAT and confirmed by an analyst for JP Morgan.
'[Researchers] would notify us if they had any safety concerns and have not done that to date, ' Dr Kathrin Jansen, Pfizer's head of vaccine research, said on the call. In India, over 30 vaccine candidates are in different stages of development, said Union Health Minister Harsh Vardhan on Monday.
The problem in the UK?
India: The Serum Institute of India (SII), which has partnered with AstraZeneca and is conducting phase 2/3 human clinical trials in the country, has not given any clarification on how it would resume the trials in the country.
Study participants will take the inoculations by inhaling them through their mouths. Researchers will be allowed some time with this step. This will be crucial to ensure safety and maintain the integrity of the trials. He had on September 14 said the Americans could get the vaccine by 2020-end if approvals come in.
Following the formula's registration, Russian Federation announced that it would be asking for volunteers to participate in a wide-ranging final trial phase, involving 40,000 muscovites.
Shares of AstraZeneca AZN.L inched higher in early trade on Monday as the optimism spurred by the British drugmaker's resumption of clinical trials for its COVID-19 vaccine candidate outweighed official weekend moves to cut US drug prices. The company has planned to expand into Japan and Russian Federation for the early to mid-stage trials. The pharmaceutical giant, along with Moderna (MRNA) and AstraZeneca (AZN), are all in the late-stage testing phase.